

antiviral and associated therapy - all results

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
ivermectin	15 studies ¹	suggested 63			
favipiravir	10 studies ²	suggested 66			
chloroquine and derivatives	8 studies ³		inconclusive results for : death D28 ; deaths ; clinical deterioration ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (time to event analysis only) ; hospital discharge ; viral clearance ; viral clearance (time to event analysis only) ; ICU admission ; recovery ; adverse events	suggested 3.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias	
azithromycin	3 studies ⁴		inconclusive results for : deaths ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (7-day) ; mechanical ventilation ; radiologic improvement (14-day) ; serious adverse events ; adverse events ; renal impairment	suggested 715.0-fold increase in viral clearance but the degree if certainty is unassessable	
nitazoxanide	3 studies ⁵		inconclusive results for : death D28 ; deaths ; clinical deterioration ; clinical improvement ; clinical improvement (7-day) ; ICU admission		
remdesivir	3 studies ⁶	demonstrated 12			

Continued on next page

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
umifenovir (arbidol)	2 studies ⁷		inconclusive results for : clinical deterioration ; radiologic improvement (14-day) ; radiologic improvement (7-day) ; viral clearance ; viral clearance by day 14 ; viral clearance by day 7 ; severe COVID-19 occurrence		
azvudine	1 study ⁸		inconclusive results for : deaths ; radiologic improvement (7-day) ; serious adverse events ; adverse events	suggested 28.5-fold increase in viral clearance but the degree if certainty is unassessable suggested 28.5-fold increase in viral clearance by day 7 but the degree if certainty is unassessable	
bromhexine	1 study ⁹		inconclusive results for : clinical deterioration ; clinical improvement (21-day) ; mechanical ventilation ; viral clearance by day 14 ; recovery	suggested 10.0-fold increase in hospital discharge but the degree if certainty is unassessable	
doxycycline	1 study ¹⁰		inconclusive results for : deaths ; recovery ; serious adverse events ; adverse events	suggested 56	
Ensitrelvir (XOCOVA)	1 study ¹¹		-		
favipiravir plus interferon	1 study ¹²		inconclusive results for : deaths ; ICU admission		

Continued on next page

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
hydroxychloroquine plus macrolides	1 study ¹³		inconclusive results for : deaths ; deaths (time to event analysis only) ; clinical deterioration ; clinical improvement ; clinical improvement (14-day) ; mechanical ventilation ; serious adverse events ; acute kidney injury ; adverse events ; arrhythmia ; elevated liver enzymes ; long QT ; Thromboembolic events		
lopinavir/ritonavir	1 study ¹⁴	demonstrated 3.2-fold increase in viral clearance	inconclusive results for : deaths ; clinical deterioration ; clinical improvement (time to event analysis only) ; mechanical ventilation ; radiologic improvement (14-day) ; radiologic improvement (7-day) ; viral clearance by day 14 ; viral clearance by day 7 ; ICU admission ; severe COVID-19 occurrence ; serious adverse events	suggested 3.9-fold increase in clinical improvement but the degree if certainty is unassessable demonstrated 4.4-fold increase in viral clearance (time to event analysis only) but the degree if certainty is unassessable	
lopinavir/ritonavir, ribavirin and interferon beta-1b	1 study ¹⁵		inconclusive results for : deaths ; serious adverse events	suggested 3.9-fold increase in clinical improvement but the degree if certainty is unassessable suggested 3.9-fold increase in clinical improvement (time to event analysis only) but the degree if certainty is unassessable demonstrated 4.4-fold increase in viral clearance but the degree if certainty is unassessable demonstrated 4.4-fold increase in viral clearance (time to event analysis only) but the degree if certainty is unassessable	

Continued on next page

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
sofosbuvir and ledipasvir	1 study ¹⁶		-		

Uncertain results are statistically significant results but obtain in trial with high risk of bias.

Demonstrated results are significant results obtained on the primary endpoint of a trial at low risk of bias or with some concerns.

Notes

¹I-TECH (Lim), 2022 (NCT04920942); Abd-Elsalam, 2021 (NCT04403555); Babalola, 2021 (); Bukhari, 2021 (NCT04392713); Kirti, 2021 (CTRI/2020/08/027225); RIVET-COV (Mohan) (12mg and 24mg), 2021 (CTRI/2020/06/026001); Ahmed, 2020 (); Chaccour, 2020 (NCT04390022); Chachar, 2020 (NCT04739410); Krolewiecki, 2020 (NCT004381884); NCT04523831 (Mahmud), 2020 (NCT04523831); Shahbaznejad, 2020 (IRCT20111224008507N3); Glorial F, 2020 (NCT04343092); Espitia-Hernandez, 2020 (); Spoorthi, 2020 ()

²FACCT Trial, 2021 (NCT04392973); Holubar M, 2021 (NCT04346628); Shenoy S, 2021 (NCT04529499); Shinkai, 2021 (JapicCTI-205238); Solaymani-Dodaran, 2021 (IRCT20200318046812N1); AVI-FAVIR, 2020 (NCT04434248); Dabbous HM, 2020 (NCT04349241); NCT04542694, 2020 (NCT04542694); Ruzhentsova T, 2020 (NCT04501783); Udwadia, 2020 (CTRI/2020/05/025114)

³FACCT Trial, 2021 (NCT04392973); Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (NCT04322123); HC-nCoV (Shanghai), 2020 (NCT04261517); Kamran, 2020 (NCT04491994); NCT04333654, 2020 (NCT04333654); NCT04342650, 2020 (NCT04342650); Zhaowei Chen, 2020 (ChiCTR2000029559); Min, 2020 ()

⁴Rashad A (AZI vs SoC), 2021 (); COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (NCT04322123); Espitia-Hernandez, 2020 ()

⁵Fontanesi, 2021 (NCT04348409); Silva, 2021 (NCT04463264); Rocco, 2020 (NCT04552483)

⁶GS-US-540-5773 (Goldman), 2020 (NCT04292899); GS-US-540-5774, 10 days, 2020 (NCT04292730); GS-US-540-5774, 5 days, 2020 (NCT04292730)

⁷ELACOI (Lopinavir/ritonavir), 2020 (NCT04252885); Yethindra, 2020 (None)

⁸Ren, 2020 (ChiCTR2000029853)

⁹Li T, 2020 (NCT04273763)

¹⁰Spoorthi, 2020 ()

¹¹Mukae - Phase 2a, 2022 (jRCT2031210350)

¹²Khamis, 2020 ()

¹³Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (NCT04322123)

¹⁴ELACOI (lopinavir/ritonavir), 2020 (NCT04252885)

¹⁵Hung et al., 2020 (NCT04276688)

¹⁶Nourian A, 2020 (IRCT20100228003449)